ライフサイエンスコーパス: patient monitoring

1 biological insights and biomarkers to guide patient monitoring.

2 to improve the ease, frequency, and depth of patient monitoring.

3 ariables have the potential to revolutionize patient monitoring.

4 g, assuming appropriate device selection and patient monitoring.

5 urements are used for glaucoma diagnosis and patient monitoring.

6 (TM) is easier to perform and allows easier patient monitoring.

7 without increasing the overall frequency of patient monitoring.

8 ssays in the context of drug development and patient monitoring.

9 is essential for both diagnosis and ongoing patient monitoring.

10 ation in the context of drug development and patient monitoring.

11 therapy improves outcomes and requires close patient monitoring.

12 re routinely acquired for health studies and patient monitoring.

13 future mechanistic studies and reproducible patient monitoring.

14 s in plasma EVs may aid cancer detection and patient monitoring.

15 quipment that had to be reused on uncohorted patients; monitoring adherence to infection control prec

16 e is known about the role of oscillometry in patient monitoring after a transplant.Objectives: To cha

17 -effective and is a recommended strategy for patient monitoring, although further empirical evidence

18 Wired technology can be cumbersome for patient monitoring and can restrict the behavior of the

19 lassification system is positioned to inform patient monitoring and care and, for the first time to o

20 edict survival and might contribute to guide patient monitoring and clinical management.

21 analysis of CTC shows promise for real-time patient monitoring and clinical outcome prediction in th

22 view of current wireless technology used for patient monitoring and disease management.

23 sults support the use of the iBox to improve patient monitoring and facilitate clinical trials in chi

24 Adverse events were recorded, and patient monitoring and laboratory assay were performed a

25 lopment of clinical programs, such as remote patient monitoring and management, may represent potenti

26 ing this physiology may facilitate long-term patient monitoring and pharmacological management to mit

27 rge laboratories, resulting in low access to patient monitoring and poor personalized treatments.

28 on edge computing to reduce response time in patient monitoring and provide a reliable method for int

29 IV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor prog

30 ebleeding, underscoring the need for careful patient monitoring and targeted intervention in these ca

31 outcomes that can then be used to streamline patient monitoring and treatment modification.

32 rs may enhance the personalization of cancer patient monitoring and treatment.

33 reduce the risk of first recurrence in NMBIC patients, monitoring and preserving their renal function

34 ists, preoperative and sedative medications, patient monitoring, and airway endoscopic techniques, as

35 ansplantation for early risk stratification, patient monitoring, and clinical trials.

36 value in terms of risk assessment, continued patient monitoring, and for therapeutic decision-making.

37 ent, enabling timely interventions, improved patient monitoring, and mitigating adverse outcomes.

38 sis diagnosis and guide treatment decisions, patient monitoring, and outcomes.

39 including data security and privacy, remote patient monitoring, and regulatory variations.

40 and translational insights for trial design, patient monitoring, and reliable detection of disease pr

41 ntributing significantly to early diagnosis, patient monitoring, and therapeutic planning.

42 roved algorithms for identifying RV failure, patient monitoring, and weaning protocols for both isola

43 fluid resuscitation, early antibiotics, and patient monitoring, are relatively inexpensive.

44 r use of one assay platform for longitudinal patient monitoring, but the data also reinforce the noti

45 rdized TM SMWT is feasible and allows easier patient monitoring, but there is a statistically signifi

46 ealthcare has the potential to revolutionize patient monitoring by providing accurate, real-time loca

47 spent 70%, 3%, 3%, and 24% of their time on patient monitoring, collaboration, system maintenance, a

48 raction with LSTM for sequential analysis of patient monitoring data, including two types of immune d

49 Patient monitoring devices should be designed to be mini

50 ase, may make these agents ideal for staging patients, monitoring disease pretherapy or posttherapy,

51 I 12-lead ECGs, providing a means to enhance patient monitoring during MR imaging and MR-guided inter

52 al care, provided that there is a continuous patient monitoring during the infusion, staff training o

53 critical care, provided there is continuous patient monitoring during the infusion, staff training o

54 ry processes in NP states and may facilitate patient monitoring during therapeutic trials related to

55 s and to clarify their utility in individual patient monitoring efforts.

56 to monitor activity and vital signs), remote patient monitoring (eg, environmental exposures and medi

57 mens, utility of the electroencephalogram in patient monitoring, emerging drug therapies and patient

58 adjusted the biomarker for standard-of-care patient monitoring factors.

59 termination prediction to enable pro-active patient monitoring for improved patient retention; (c) m

60 The US FDA has required patient monitoring for RCR, and the National Gene Vector

61 efinite complication of RLT, suggesting that patient monitoring for TLS should be mandatory.

62 U.S. safety data from patient monitoring forms submitted to the esketamine Ris

63 aims data to assess trends in general remote patient monitoring from January 2018 through September 2

64 h care providers and pharmacy certification, patient monitoring (from Patient Status Forms, based par

65 gether with an increased awareness of remote patient monitoring, has accelerated the impact of digita

66 This highlights the need for careful patient monitoring in all immunosuppressive settings at

67 ch directions and methods that could improve patient monitoring in clinical practice.

68 To facilitate patient monitoring in order to avoid or delay the occurr

69 clues for preclinical safety assessment and patient monitoring in trials of stem cell therapies.

70 Patient monitoring included serial HLA single-antigen te

71 Patient monitoring includes time adapted HR, SO(2), ECG,

72 lth, telemedicine, mobile health, and remote patient monitoring), Internet access, and cellular techn

73 Remote patient monitoring is a critical component of digital me

74 ular assays to improve disease diagnosis and patient monitoring is a critical need.

75 tation, early antibiotic administration, and patient monitoring is limited by lack of supplies and sk

76 added clinical value beyond standard of care patient monitoring is unclear.

77 methods hold great potential for stratifying patients, monitoring MS progression, and determining the

78 receive home-based care, which consisted of patient monitoring of blood pressure, home visits from a

79 ensitive, information-rich assays that allow patient monitoring of immune responses, tumor regression

80 -harm but underscore the necessity for close patient monitoring of self-harm throughout the gabapenti

81 Reliable patient monitoring of viral loads requires the detection

82 Standard episodic patient monitoring of vital signs on the medical-surgica

83 starts <1 month after diagnosis) and remote patient monitoring on glycemia in young people with newl

84 < 0.0001) independently of standard of care patient monitoring parameters.

85 biomarkers against standard-of-care routine patient monitoring parameters.

86 th patient care (appropriate prescribing and patient monitoring), patient behavior (adherence), and c

87 ults, we further study the optimal length of patient monitoring periods for different prediction hori

88 The impact of remote patient monitoring platforms to support the postoperativ

89 The adequacy of current patient monitoring practices and the potential to improv

90 are highly relevant for such applications as patient monitoring, proper use of therapeutic guidelines

91 Remote patient monitoring represents a paradigm shift in the wa

92 of their added value beyond standard of care patient monitoring requires further study.

93 Current guidelines recommend using remote patient monitoring (RPM) for implantable cardioverter-de

94 lantable defibrillators (ICD), use of remote patient monitoring (RPM) is associated with lower risk o

95 ed the association between the use of remote patient monitoring (RPM) of implantable cardioverter def

96 Health care systems have implemented remote patient monitoring (RPM) programs to manage patients wit

97 Digital remote patient monitoring (RPM), such as home-based blood press

98 (eg, clinical services, adherence services, patient monitoring services) and clinic characteristics

99 very (clinical services, adherence services, patient monitoring services, e.g.) and clinic characteri

100 sessed the cost-effectiveness of alternative patient monitoring strategies.

101 ltiancestry samples of individuals from a UK patient monitoring system, CLOZUK2 (n = 3133) and CLOZUK

102 research have included intelligent agents in patient monitoring systems by integrating blockchain tec

103 lored for the purpose of facilitating remote patient monitoring systems within the context of a 5G en

104 he design of remote telemetry work and other patient monitoring tasks in critical and intermediate ca

105 f clinically useful management platforms for patient monitoring that can be integrated into health ca

106 Two standards were used in measuring patient monitoring: the Health Plan Employer Data and In

107 digital medicine is the promise of improved patient monitoring to allow assessment and personalized

108 farction, from diagnosis and misdiagnosis to patients' monitoring, treatment, and potential complicat

109 nitiate therapy, choice of initial regimens, patient monitoring, when to change therapy, and how best

110 , selection of appropriate initial regimens, patient monitoring, when to change therapy, and what reg

111 ial, FT screening as part of routine digital patient monitoring with PROs reduced the development, or